Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute
- PMID: 31622969
- DOI: 10.1159/000502681
Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute
Abstract
Introduction: Small-cell lung cancer (SCLC) is a very chemosensitive solid tumor but is characterized by rapid progression. The modified Glasgow prognostic score (mGPS) has been shown to be an independent prognostic factor in various tumors. However, there have been few reports regarding the prognostic value of mGPS in extensive disease (ED)-SCLC.
Objective: This study was designed to clarify the clinical significance of mGPS focusing on its usefulness as a prognostic indicator for the survival and serial administrations of chemotherapies in patients with ED-SCLC.
Methods: We retrospectively analyzed the clinical records of ED-SCLC patients diagnosed and treated at Shinshu University School of Medicine between January 2005 and December 2018. Overall survival (OS) was compared according to mGPS and we examined whether mGPS could be a prognostic factor in ED-SCLC using the Kaplan-Meier method and univariate and multivariate Cox hazard analyses.
Results: Eighty-three patients were enrolled in this study. The median OS of mGPS 0, mGPS 1, and mGPS 2 groups were 13.6, 9.2, and 5.7 months, respectively. The OS of the mGPS 0 group was significantly longer than those of mGPS 1 and mGPS 2 groups (log-rank, p = 0.025 and 0.008, respectively). The rates of second-line chemotherapy administration in mGPS 0, mGPS 1, and mGPS 2 groups were 79.4, 61.9, and 33.3%, respectively. The rate in the mGPS 0 group was significantly higher than that in the mGPS 2 group (p = 0.003). Multivariate analyses indicated that mGPS 2 was an independent unfavorable prognostic factor in addition to old age (≥75 years), poor performance status (2-3), and elevated serum lactate dehydrogenase level (≥223 IU/L).
Conclusion: In ED-SCLC patients, mGPS was useful as a prognostic indicator for OS.
Keywords: Chemotherapy; Inflammatory response; Nutrition; Overall survival; Prognostic factor.
© 2019 S. Karger AG, Basel.
Similar articles
-
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.Lung Cancer. 2012 Dec;78(3):276-81. doi: 10.1016/j.lungcan.2012.09.002. Epub 2012 Oct 6. Lung Cancer. 2012. PMID: 23043970
-
A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer.Tumour Biol. 2015 Jan;36(1):337-43. doi: 10.1007/s13277-014-2623-4. Epub 2014 Sep 26. Tumour Biol. 2015. PMID: 25256672
-
Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer.Thorac Cancer. 2020 Jun;11(6):1578-1586. doi: 10.1111/1759-7714.13432. Epub 2020 Apr 14. Thorac Cancer. 2020. PMID: 32286017 Free PMC article.
-
High pretreatment D-dimer level is an independent unfavorable prognostic factor of small cell lung cancer: A systematic review and meta-analysis.Medicine (Baltimore). 2021 Apr 16;100(15):e25447. doi: 10.1097/MD.0000000000025447. Medicine (Baltimore). 2021. PMID: 33847650 Free PMC article.
-
Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies.Respir Investig. 2023 Jan;61(1):74-81. doi: 10.1016/j.resinv.2022.10.003. Epub 2022 Nov 29. Respir Investig. 2023. PMID: 36460585 Review.
Cited by
-
C-PLAN index as a prognostic factor for patients with previously untreated advanced non-small cell lung cancer who received combination immunotherapy: A multicenter retrospective study.Thorac Cancer. 2023 Feb;14(6):636-642. doi: 10.1111/1759-7714.14798. Epub 2023 Jan 12. Thorac Cancer. 2023. PMID: 36635979 Free PMC article.
-
Predictive strength of inflammatory scores for in-hospital mortality in infective endocarditis.Herz. 2025 Jun;50(3):192-198. doi: 10.1007/s00059-024-05292-9. Epub 2025 Jan 24. Herz. 2025. PMID: 39853409 English.
-
Glasgow prognostic score for prediction of chemotherapy-triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer.Thorac Cancer. 2021 Jun;12(11):1681-1689. doi: 10.1111/1759-7714.13900. Epub 2021 May 3. Thorac Cancer. 2021. PMID: 33939332 Free PMC article.
-
Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.Front Oncol. 2023 Jan 20;12:1080729. doi: 10.3389/fonc.2022.1080729. eCollection 2022. Front Oncol. 2023. PMID: 36741711 Free PMC article.
-
Prognostic and clinical significance of modified glasgow prognostic score in pancreatic cancer: a meta-analysis of 4,629 patients.Aging (Albany NY). 2021 Jan 6;13(1):1410-1421. doi: 10.18632/aging.202357. Epub 2021 Jan 6. Aging (Albany NY). 2021. PMID: 33406501 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical